← Back to Screener
Annexon, Inc. Common Stock (ANNX)
Price$6.33
Favorite Metrics
Price vs S&P 500 (26W)97.60%
Price vs S&P 500 (4W)11.34%
Market Capitalization$1.02B
All Metrics
Book Value / Share (Quarterly)$1.42
P/TBV (Annual)0.63x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.25
Price vs S&P 500 (YTD)23.85%
EPS (TTM)$-1.34
10-Day Avg Trading Volume2.53M
EPS Excl Extra (TTM)$-1.34
EPS (Annual)$-1.33
ROI (Annual)-97.66%
Cash / Share (Quarterly)$1.60
ROA (Last FY)-74.46%
EBITD / Share (TTM)$-1.38
ROE (5Y Avg)-63.20%
Cash Flow / Share (Annual)$-1.25
P/B Ratio4.81x
P/B Ratio (Quarterly)3.43x
Net Income / Employee (Annual)$-2
ROA (TTM)-76.96%
EPS Incl Extra (Annual)$-1.33
Current Ratio (Annual)5.68x
Quick Ratio (Quarterly)5.59x
3-Month Avg Trading Volume2.69M
52-Week Price Return315.03%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.95
52-Week High$7.18
EPS Excl Extra (Annual)$-1.33
CapEx CAGR (5Y)-21.51%
Tangible BV CAGR (5Y)142.45%
26-Week Price Return101.59%
Quick Ratio (Annual)5.59x
13-Week Price Return14.21%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)5.68x
Enterprise Value$856.961
Book Value / Share Growth (5Y)-30.92%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.60
3-Month Return Std Dev78.71%
Net Income / Employee (TTM)$-2
ROE (Last FY)-97.66%
EPS Basic Excl Extra (Annual)$-1.33
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.34
ROI (TTM)-101.33%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$4.84
Price vs S&P 500 (52W)285.20%
Year-to-Date Return26.49%
5-Day Price Return3.42%
EPS Normalized (Annual)$-1.33
ROA (5Y Avg)-50.85%
Month-to-Date Return14.62%
Cash Flow / Share (TTM)$-1.87
EBITD / Share (Annual)$-1.38
ROI (5Y Avg)-63.20%
EPS Basic Excl Extra (TTM)$-1.34
P/TBV (Quarterly)0.92x
P/B Ratio (Annual)3.43x
Book Value / Share (Annual)$1.42
Price vs S&P 500 (13W)13.52%
Beta1.27x
Revenue / Share (TTM)$0.00
ROE (TTM)-101.33%
52-Week Low$1.40
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.19
4.19
4.19
4.19
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ANNXAnnexon, Inc. Common Stock | — | — | — | — | $6.33 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Annexon Inc is a clinical-stage biopharmaceutical company developing C1q inhibitors to treat complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders. The company's platform technology targets the classical complement pathway across multiple disease areas affecting the body, brain, and eye. Its pipeline includes product candidates ANX005, ANX007, ANX009, and ANX1502 in development.